Biomarkers of Renal Cancer
Biorek S.R.L.
1,000 participants
Jun 11, 2019
OBSERVATIONAL
Conditions
Summary
The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe). This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.
Eligibility
Inclusion Criteria8
- Men and women over 18 years of age
- Diagnosis of first episode of renal mass
- Caucasian race
- Signed, informed consent
- Men and women over 18 years of age
- Caucasian race
- Living kidney donor or patient with urological functional diseases (e.g. kidney stones, benign prostate hypertrophy, etc..)
- Signed, informed consent
Exclusion Criteria9
- Any other concomitant cancer or history of active cancer in the last 5 years
- Oncological genetic syndrome
- Previous history of renal tumour
- Urothelial cancer
- End-stage renal disease on hemodialysis
- Bilateral renal cell carcinoma
- History of active cancer in the last 5 years
- Oncological genetic syndrome
- End-stage renal disease on hemodialysis or peritoneal dialysis
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05785052